Verrica Pharmaceuticals Valuation
| VRCA Stock | USD 1.00 0.01 1.01% |
Today, the company appears to be undervalued. Verrica Pharmaceuticals has a current Real Value of $3.91 per share. The regular price of the company is $1.0. Our model measures the value of Verrica Pharmaceuticals from inspecting the company fundamentals such as Current Valuation of 69.5 M, shares owned by insiders of 16.20 %, and Return On Equity of -20.6 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Verrica Pharmaceuticals' valuation include:
Price Book 238.5425 | Enterprise Value 69.5 M | Enterprise Value Ebitda (11.70) | Price Sales 4.924 | Enterprise Value Revenue 7.5466 |
Undervalued
Today
Please note that Verrica Pharmaceuticals' price fluctuation is dangerous at this time. Calculation of the real value of Verrica Pharmaceuticals is based on 3 months time horizon. Increasing Verrica Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Verrica Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Verrica Stock. However, Verrica Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0 | Real 3.91 | Target 12.67 | Hype 0.98 | Naive 1.27 |
The real value of Verrica Stock, also known as its intrinsic value, is the underlying worth of Verrica Pharmaceuticals Company, which is reflected in its stock price. It is based on Verrica Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Verrica Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Verrica Pharmaceuticals helps investors to forecast how Verrica stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Verrica Pharmaceuticals more accurately as focusing exclusively on Verrica Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Verrica Pharmaceuticals' intrinsic value based on its ongoing forecasts of Verrica Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Verrica Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Verrica Pharmaceuticals we suggest using both methods to arrive at a better estimate.
Verrica Pharmaceuticals Cash |
|
Verrica Valuation Trend
Comparing Verrica Pharmaceuticals' enterprise value against its market capitalization is a good way to estimate the value of Verrica Pharmaceuticals uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Verrica Pharmaceuticals Total Value Analysis
Verrica Pharmaceuticals is at this time forecasted to have valuation of 69.5 M with market capitalization of 45.35 M, debt of 45.51 M, and cash on hands of 14.4 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Verrica Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
69.5 M | 45.35 M | 45.51 M | 14.4 M |
Verrica Pharmaceuticals Investor Information
About 16.0% of the company outstanding shares are owned by insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.03. Verrica Pharmaceuticals recorded a loss per share of 1.84. The entity had not issued any dividends in recent years. Based on the key indicators related to Verrica Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Verrica Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Verrica Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Verrica Pharmaceuticals has an asset utilization ratio of 6.28 percent. This suggests that the Company is making $0.0628 for each dollar of assets. An increasing asset utilization means that Verrica Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Verrica Pharmaceuticals Ownership Allocation
Verrica Pharmaceuticals shows a total of 45.6 Million outstanding shares. Verrica Pharmaceuticals has 16.2 % of its outstanding shares held by insiders and 16.42 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Verrica Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 5.12 M. Net Loss for the year was (67 M) with profit before overhead, payroll, taxes, and interest of 8.31 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Verrica Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Verrica Pharmaceuticals and how it compares across the competition.
About Verrica Pharmaceuticals Valuation
The stock valuation mechanism determines Verrica Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Verrica Pharmaceuticals. We calculate exposure to Verrica Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Verrica Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 4.4 M | 3.3 M | |
| Pretax Profit Margin | (13.07) | (13.73) | |
| Operating Profit Margin | (12.83) | (13.48) | |
| Net Loss | (13.07) | (13.73) | |
| Gross Profit Margin | 0.85 | 1.00 |
Verrica Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 45.3 M |
Verrica Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Verrica Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Verrica we look at many different elements of the entity such as Verrica's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Verrica Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Verrica Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Verrica Pharmaceuticals' worth.Complementary Tools for Verrica Stock analysis
When running Verrica Pharmaceuticals' price analysis, check to measure Verrica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verrica Pharmaceuticals is operating at the current time. Most of Verrica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Verrica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verrica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Verrica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |